In order to evaluate whether mPEG × HER2-modified PLD can efficiently enter into the nucleus of HER2+ ovarian tumor cells, we further intravenously treated PLD, mPEG × HER2- or mPEG × DNS-modified PLD to SKOV-3-xenografted nude mice and collected the tumor tissue for detecting the doxorubicin signal at 48 h after drug treatment. The gene discussed is ERBB2; the disease is ovarian neoplasm.